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A B S T R A C T
Rabies vaccine strain was isolated from a red fox (Vulpes vulpes) with signs of neurological disorder during
an oral vaccination campaign in 2015, Hungary. The whole genome sequence of the isolated strain shared
>99.9% nucleotide sequence identity to the whole genomes of vaccines strains recently used in Hungarian oral
vaccination campaigns. The neuroinvasive potential of rabies vaccines that leads to development of clinical
manifestations is rarely seen among wild animals; however, the observed residual pathogenicity needs aware-
ness of field experts and requires close monitoring of rabies cases in areas where elimination programs are
implemented.
© 2019.
Since the 1980’s oral immunization of wildlife by vaccine baits has
helped numerous European countries to control and eliminate sylvatic
rabies [1]. In most of the countries, live attenuated vaccine strains
have been used [2–6]. These vaccines have originated from the Eve-
lyn Rokitnicki Abelseth (ERA) virus strain derived from the original
Street Alabama Dufferin (SAD) virus that was isolated from a rabid
dog [7]. Oral vaccination campaigns (ORV) in Hungary starting from
1992 were performed using different SAD-based vaccine baits (SAD
B19 in Fuchsoral, IDT Biologika GmbH; SAD P5/88 in Rabifox, IDT
Biologika GmbH; SAG 1 in SAG1 in Oral Fox Vaccine, Virbac) [8].
The SAD Bern (Lysvulpen, Bioveta) vaccines have been in use since
2008 [1,9].
Residual pathogenicity of live rabies vaccines currently used in
wildlife has been observed for SAD P5/88 [2], SAD B19 [2,10], SAD
Bern [11,12], and ERA [13], therefore, rabies viruses isolated from an-
imals in a vaccination area needs to be characterized to identify possi-
ble vaccine-induced rabies cases [13–15].
In a region of south-eastern Hungary (Csabaszabadi, Békés
county) where vaccination campaigns are routinely carried out, a one
and a half years old red fox (Vulpes vulpes) with altered behaviour
was observed in November 2015. The fox showed unsteady behav-
iour and moved wobblingly. After shooting the apparently ill animal,
the carcass was transferred to the Veterinary Diagnostic Department
of the National Food Chain Safety Office. Recommended as well as
traditional techniques were used for differential diagnosis of rabies as
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detailed elsewhere [14,16]. In brief, the methods we utilized included
immunofluorescence antibody test (FAT) performed on smears of
spinal bulb and cortex and mouse inoculation test (MIT); FAT gave
positive results whereas in MIT assay 7days post infection dyspnoea,
ataxia and exsiccosis were observed in specific-pathogen-free NMRI
mice. A total of 6 mice were inoculated via intracranial route and
were observed up to 28days post infection. All 6 mice showed clin-
ical signs between 9 and 12days post infection and were humanely
euthanized at the end of observation. Histopathological examination
of brain slices showed cellular aggregations consisting of glial cells
around medulla oblongata (i.e. Babes nodules; data not shown). Ra-
bies virus (RABV) isolation was performed on N2a cells. The pres-
ence of RABV RNA in the homogenized brain specimens of fox and
mice was demonstrated by reverse-transcription PCR and direct se-
quencing of short genomic sequences encoding the nucleoprotein (N
gene) and the glycoprotein (G gene) [17–20]. A newly developed
DIVA-TaqMan RT-PCR assay to differentiate between vaccine strain
and wild-type RABV strains circulating in Hungary was also uti-
lized (see Supplementary file). ELISA test (Platelia™ RabiesII Kit,
Bio-Rad) showed greater than 0.5 equivalent units per ml serum IgG
titer of the shot red fox specimen [21]. The routine method for age de-
termination in foxes was counting the layers of cementum in sections
of canine teeth under 40× magnification [22,23]. In addition, tetra-
cycline marker (TCM) examination of the canine teeth indicated that
the animal consumed bait during a preceding immunization campaign
(data not shown) [24].
After sequencing of the partial N and G genes we observed that the
Csabaszabadi RABV sample (Csabaszabadi denotes the nearest set-
tlement to the location were the rabid red fox was identified) clus-
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Fig. 1. Nucleoprotein gene based phylogenetic tree generated with Kimura 2-parameter substitution model with gamma distribution and maximum likelihood statistical method us-
ing 1000 bootstraps. The Hungarian Csabaszabadi sample (blue square) cluster with the SADBern Lysvulpen sequence and not with wild-type RABV strains detected over the past
decade in Hungary (empty circles) or neighboring countries. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
quences identified over the past two decades in Hungary (Fig. 1).
This preliminary analysis also demonstrated sequence divergence be-
tween the reference Lysvulpen vaccine sequence and the Csabasz-
abadi RABV. Therefore, we decided to perform full genome sequenc-
ing of the isolated RABV strain and five batches of the Lysvulpen
vaccine (0519, 1819, 6321, 0922, 0622). The sequenced vaccine virus
strains were manufactured between April 2012 and July 2015. Among
the batches produced during 2015, #0622 and #0922 were used in
the autumn campaign of ORV in Hungary. Regarding the Csabasz-
abadi RABV strain we determined the genome derived from cell cul-
ture isolates (after passage #2) as well as the genome of the re-iso-
lated strain from mouse brain. For each RABV isolate we ampli-
fied partially overlapping genomic regions using six primer pairs
(Table S1). Then, amplicons belonging to the same isolate were mixed
and subjected to whole genome sequencing by using published pro-
tocols of semiconductor sequencing on an Ion Torrent PGM [25,26].
As a result, 11,874 base pair long genomic sequences were obtained
(GenBank accession numbers, MK111075–MK111080). When an-
alyzing the genomic sequences, >99.9% nucleotide sequence iden-
tities were found among the Csabaszabadi RABV isolate and the
Lysvulpen vaccine strains whose sequences were determined in this
study. Whole-genome sequence based phylogenetic tree was gener-
ated to compare the Hungarian origin sequences to reference vac-
cine sequences (Fig. 2). Phylogenetic analysis of whole genome se-
quences showed that Lysvulpen vaccine batches used during most re-
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Fig. 2. Whole genome based phylogenetic tree generated with Tamura-3 substitution model and maximum likelihood statistical method using 1000 bootstraps. The Hungarian
Csabaszabadi sample (blue square) and the vaccine strains used in Hungary (black circles) cluster with SAD B19, SAG2, SAD VA1, and SAD P5/88 vaccines. In contrast, the original
Lysvulpen vaccine (black diamond) clusters with SAD Bern vaccines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
specimen are more closely related to the SAD Bern based vaccine
viruses (≥99.9% nt similarity, ≤6 nt substitutions) than to the origi-
nal Lysvulpen vaccine strain (GenBank accession number, EF206708;
∼99.7% nt similarity, 27–30 nt substitutions). In previous studies sim-
ilar findings were reported about the genetic relationships among SAD
Bern strain and vaccine derived field isolates and deeper analyses of
available sequence data suggested that some of the commercial vac-
cines exist as a mixture of variants [27–29]. This observation may ex-
plain why a SAD B19-like vaccine strain was found in several batches
of Lysvulpen. Moreover, sequencing of different batches of Lysvulpen
vaccines may help fully resolve the history and population structure of
currently used rabies vaccines across Europe.
In summary, oral rabies vaccines containing live replication-com-
petent attenuated virus strains may cause vaccine-induced rabies [14].
Examples include the attenuated SAD Bern, SAD B19, and SAD
P5/88 vaccines which can be pathogenic for some rodent species
during cerebral, muscular and oral inoculation route [2,30–33]. In
addition, sporadic SAD Bern or SAD B19 vaccine associated field
cases in wildlife were reported from Austria, Germany, Latvia, Ro-
mania, Slovenia, and Switzerland following oral rabies vaccination
campaigns [2,11,12,15,29]. Thus, despite the good safety profile, au-
thorities and field experts need to be aware that oral rabies vaccines
may possess some residual pathogenicity and represent potential risk
of vaccine-associated rabies. In this paper we report a vaccine-induced
rabies case in Hungary, the first case identified since the implementa-
tion of ORV based rabies elimination program launched in our coun-
try. The high genome sequence similarity among the Csabaszabadi
red fox RABV isolate and the Lysvulpen vaccine strains used in the
ORV programs together with the positive TCM test suggested that
this isolated Hungarian case was caused by infection from the vaccine
strain most likely during the campaign in autumn 2015. The affected
animal was a bit older than expected given that vaccine-associated ra-
bies cases are detected predominantly in juvenile animals [2,10,29].
Unfortunately, we did not have the opportunity to examine the sali-
vary gland tissues of the shot red fox; in this regard speculations re-
main whether red foxes could acquire vaccine virus from the bite of
an animal which consumed vaccine baits and subsequently continue to
transmit this virus to other hosts [10]. Nonetheless, literature data are
not conclusive concerning the vaccine-strain transmission potential of
red foxes as it has been demonstrated that salivary glands may test
negative by PCR in experimentally infected animals [2]. Apparently
further investigations are required to understand virus and host genetic
factors that contribute to the development of neurovirulence and trans-
missibility of vaccine-strains via salivary glands. Collectively, even
though published reports on residual pathogenicity of SAD Bern vac-
cines associated with ORV in wildlife are scarce, this additional case
from Hungary emphasizes the need for extended screening to detect
such cases in the field.
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